Haematological Cancers and the risk of severe COVID-19: Exploration and critical evaluation of the evidence to date.

摘要: From the outset of COVID-19 pandemic, patients and healthcare professionals have been concerned that a history haematological malignancy will lead to an increased risk severe COVID-19. This led UK government advising with blood cancers shield, massive re-organisation NHS haematology cancer services, changes in treatment plans for thousands patients. Given unknown effects relaxation social-distancing measures on infection rate, we review evidence date see whether is associated Multivariable analysis large population studies, taking other known factors into account, do indicate malignancy, especially those diagnosed recently, are at death from compared general population. The this higher than solid malignancies conflicting. There suggestive smaller cohort studies myeloid may be within population, but needs confirmed larger studies. Ongoing collaborative efforts required gain further regarding specific complications